Skip to main content

atazanavir

Generic: ATAZANAVIR SULFATE·Brand: ATAZANAVIR SULFATE, Evotaz, REYATAZ, Reyataz

atazanavir: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

atazanavir evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect atazanavir to BMY; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could atazanavir → BMY affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

HIV Infections

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
BRISTOL MYERS SQUIBB CO (BMY)Approved
BRISTOL MYERS SQUIBB CO (BMY)Approved
Clinical Trials (1)

Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3

NCT00528060·Phase 2
Completed

Primary endpoint: pharmacokinetic parameters of atazanavir (ATV) when combined with ritonavir (RTV) and tenofovir/emtricitabine

Interventionalopen35 enrolledStarted 2008-01Completion 2008-112 sites · FranceFrench National Agency for Research on AIDS and Viral Hepatitis
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE REYATAZ ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. Limitations of Use: • REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations (8.4) ] . • Use of REYATAZ with ritonavir in treatment-experienced patients should be guided by the number of baseline p(BMY)FDA ↗
NDA206352Type 3 - New Dosage FormPriorityOralPowder

Frequently asked questions

Who is developing atazanavir?

atazanavir is being developed by BRISTOL MYERS SQUIBB CO.

How many clinical trials involve atazanavir?

BioSniper tracks 1 clinical trial involving atazanavir.

What is atazanavir's latest FDA decision?

The most recent tracked FDA decision for atazanavir is Approval for 1 INDICATIONS AND USAGE REYATAZ ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. Limitations of Use: • REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations (8.4) ] . • Use of REYATAZ with ritonavir in treatment-experienced patients should be guided by the number of baseline p, dated June 2, 2014.